Apolipoprotein M: Progress in understanding its regulation and metabolic functions

References

• Raper J., Fung R., Ghiso J., Nussenzweig V., Tomlinson S. Characterization of a novel trypanosome lytic factor from human serum. Infect Immun 1999; 67: 1910–16
   PubMed Web of Science ®Google Scholar
• Draganov D. I., Stetson P. L., Watson C. E., Billecke S. S., La Du B. N. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein‐associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000; 275: 33435–42
   PubMed Web of Science ®Google Scholar
• Watson A. D., Berliner J. A., Hama S. Y., La Du B. N., Faull K. F., Fogelman A. M., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein1. J Clin Invest 1995; 96: 2882–91
   PubMed Web of Science ®Google Scholar
• Barlage S., Frohlich D., Bottcher A., Jauhiainen M., Muller H. P., Noetzel F., et al. ApoE‐containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J Lipid Res 2001; 42: 281–90
   PubMed Web of Science ®Google Scholar
• Dahlback B., Nielsen L. B. Apolipoprotein M – a novel player in high‐density lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 2006; 17: 291–5
   PubMed Web of Science ®Google Scholar
• Duan J., Dahlback B., Villoutreix B. O. Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site‐directed mutagenesis. FEBS Lett 2001; 499: 127–32
   PubMed Web of Science ®Google Scholar
• Karlsson H., Leanderson P., Tagesson C., Lindahl M. Lipoproteomics I: mapping of proteins in low‐density lipoprotein using two‐dimensional gel electrophoresis and mass spectrometry. Proteomics 2005; 5: 551–65
   PubMed Web of Science ®Google Scholar
• Xu N., Dahlback B. A novel human apolipoprotein (apoM). J Biol Chem 1999; 274: 31286–90
   PubMed Web of Science ®Google Scholar
• Sorenson R. C., Bisgaier C. L., Aviram M., Hsu C., Billecke S., La Du B. N. Human serum Paraoxonase/Arylesterase's retained hydrophobic N‐terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A‐I stabilizes activity. Arterioscler Thromb Vasc Biol 1999; 19: 2214–25
   PubMed Web of Science ®Google Scholar
• Christoffersen C., Nielsen L. B., Axler O., Andersson A., Johnsen A. H., Dahlback B. Isolation and characterization of human apolipoprotein M‐containing lipoproteins. J Lipid Res 2006 May 8
   PubMed Web of Science ®Google Scholar
• Zhang X. Y., Dong X., Zheng L., Luo G. H., Liu Y. H., Ekstrom U., et al. Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. Acta Histochem 2003; 105: 67–72
   PubMed Web of Science ®Google Scholar
• Faber K., Axler O., Dahlback B., Nielsen L. B. Characterization of apoM in normal and genetically modified mice. J Lipid Res 2004; 45: 1272–8
   PubMed Web of Science ®Google Scholar
• Zhang X. Y., Jiao G. Q., Hurtig M., Dong X., Zheng L., Luo G. H., et al. Expression pattern of apolipoprotein M during mouse and human embryogenesis. Acta Histochem 2004; 106: 123–8
   PubMed Web of Science ®Google Scholar
• Liang C. P., Tall A. R. Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J Biol Chem 2001; 276: 49066–76
   PubMed Web of Science ®Google Scholar
• Luo G., Hurtig M., Zhang X., Nilsson‐Ehle P., Xu N. Leptin inhibits apolipoprotein M transcription and secretion in human hepatoma cell line, HepG2 cells. Biochim Biophys Acta 2005; 1734: 198–202
   PubMed Web of Science ®Google Scholar
• Xu N., Nilsson‐Ehle P., Ahren B. Suppression of apolipoprotein M expression and secretion in alloxan‐diabetic mouse: partial reversal by insulin. Biochem Biophys Res Commun 2006; 342: 1174–7
   PubMed Web of Science ®Google Scholar
• Xu N., Ahren B., Jiang J., Nilsson‐Ehle P. Down‐regulation of apolipoprotein M expression is mediated by phosphatidylinositol 3‐kinase in HepG2 cells. Biochim Biophys Acta 2006; 1761: 256–60
   PubMed Web of Science ®Google Scholar
• Richter S., Shih D. Q., Pearson E. R., Wolfrum C., Fajans S. S., Hattersley A. T., et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor‐1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003; 52: 2989–95
   PubMed Web of Science ®Google Scholar
• Shih D. Q., Bussen M., Sehayek E., Ananthanarayanan M., Shneider B. L., Suchy F. J., et al. Hepatocyte nuclear factor‐1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet 2001; 27: 375–82
   PubMed Web of Science ®Google Scholar
• Wolfrum C., Poy M. N., Stoffel M. Apolipoprotein M is required for pre beta‐HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nature Medicine 2005; 11: 418–22
   PubMed Web of Science ®Google Scholar
• Faber K., Hvidberg V., Moestrup S. K., Dahlback B., Nielsen L. B. Megalin is a receptor for apolipoprotein M, and kidney‐specific megalin‐deficiency confers urinary excretion of apolipoprotein M. Mol Endocrinol 2006; 20: 212–18
   PubMedGoogle Scholar